Clinical Trial Update: The Transendocardial Autologous Cells (hMSC or hBMC) in Ischemic Heart Failure Trial (TAC-HFT) [Phase 1, Phase 2]

View source ↗

Summary

Update on TAC-HFT, a Phase 1/2 trial evaluating transendocardial delivery of autologous cells (hMSC/hBMC) in ischemic heart failure; the study completed and res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ischemic Heart Failure

Drugs mentioned

• Transendocardial autologous cell therapy (hMSC or hBMC) (Autologous mesenchymal stem cells; autologous bone marrow cells)

Snippet

Sponsor: University of Miami | Conditions: Stem Cell Transplantation, Ventricular Dysfunction, Left | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2015-12-14